- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01351753
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (REVIVE)
Does Reversal of Visceral Obesity by Drug Therapy Improve Vascular Function?
Obesity is common (>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions. Partly it is due to the limited efficacy and safety problems of existing pharmacotherapy. Only one drug, orlistat, is approved for long-term use in obesity; but its effects on weight are relatively small. There are drugs that have been approved for other diseases but which also reduce weight. One promising approach to treating obesity is combination therapy with orlistat and one or more of these other agents. The investigators propose an innovative approach to developing new therapies for obesity coupling the use of combination therapy with rigorous assessment of cardiovascular safety. Vascular function is a quantitative surrogate clinical endpoint that has been strongly and independently linked to future cardiovascular events.
Our hypothesis is that combination pharmacotherapy will reduce weight and improve vascular function in obese human subjects. The co-primary endpoints will be weight and vascular function.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52241
- University of Iowa Hospitals and Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 40 to 75 years
- Male or postmenopausal female
- BMI ≥ 30 kg/m2
- One or more major cardiovascular (CV) risk factors (hypertension, dyslipidemia, impaired glucose tolerance OR metabolic syndrome)
Exclusion Criteria:
- Congestive heart failure
- Renal impairment
- History of bariatric surgery (i.e. lap-band, Roux-en-Y or biliopancreatic diversion)
- Type I diabetes mellitus
- Weight loss > 10% in the past 6 months
- Recurrent nephrolithiasis
- Current treatment for seizure disorder
- Hepatic cirrhosis
- Current use of study medications
- Current use of oral estrogen
- History of smoking cessation in the past three months
- Current cholestasis or malabsorption syndrome
- Planned use of any herbal or over-the-counter supplements for weight loss
- History of allergic reactions to metformin, topiramate, orlistat or any of ingredients
- Medical conditions requiring continuous use of phosphodiesterase inhibitors and/or the inability to withhold phosphodiesterase inhibitors for 48 hours
- Participation in another clinical drug study within four weeks prior to this investigation.
- Participation in any other weight loss or rigorous exercise program.
- Any disease or condition that in the opinion of the investigator may interfere with completion of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo pills and capsules for metformin, orlistat and topiramate
|
Experimental: Topiramate
|
|
Active Comparator: Metformin
|
|
Experimental: Metformin + Orlistat
|
|
Experimental: Metformin + Topiramate
|
|
Experimental: Metformin + Topiramate + Orlistat
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight (% Change From Baseline)
Time Frame: 6 months
|
Weight obtained in the fasting state on a gowned subject.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Office Systolic Blood Pressure (mmHg Change From Baseline)
Time Frame: 6 months
|
Automated sphygmomanometry while sitting
|
6 months
|
Waist (cm Change After 6 Months From Baseline)
Time Frame: 6 months
|
Body fat distribution measured using anthropometry (waist, neck and hip circumferences)
|
6 months
|
Carotid-femoral Pulse Wave Velocity (PWV)(Change After 6 Months From Baseline)
Time Frame: 6 months
|
Change in carotid-femoral pulse wave velocity (Sphygmocor).
|
6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Insulin Resistance
- Hyperinsulinism
- Angina Pectoris
- Obesity
- Metabolic Syndrome
- Microvascular Angina
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Lipid Regulating Agents
- Anticonvulsants
- Anti-Obesity Agents
- Metformin
- Topiramate
- Orlistat
Other Study ID Numbers
- 201012738
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Topiramate
-
Johnson & Johnson Taiwan LtdCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Supernus Pharmaceuticals, Inc.Completed
-
University of CopenhagenR W Johnson Pharmaceutical Research InstituteTerminated
-
Montefiore Medical CenterOrtho-McNeil PharmaceuticalCompletedObsessive-compulsive DisorderUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...TerminatedObesity | Hypertriglyceridemia | Hyperlipidemia
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedEpilepsy | Seizures | Epilepsies, Partial